Shisi Pharmaceutical Group (02005) has obtained drug production registration approval for linezolid dry suspension (5ml: 100mg)
Shisi Pharmaceutical Group (02005) issued an announcement. The group has obtained the relevant linezolamide dry mix from the China National Drug Administration...
Is SSY Group (HKG:2005) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
Zhitong Hong Kong Shareholders' Rights Disclosure | April 19
Disclosure of Hong Kong Stock Shareholders' Rights | April 19
Shi Siyao Group (02005.HK) was increased by 1 million shares by executive director Qu Jiguang
Gelonghui, April 19丨According to the latest equity disclosure data of the Stock Exchange, on April 18, 2024, Shijiyao Group (02005.HK) obtained an increase of 1 million shares by Executive Director Qu Jiguang at an average price of HK$4.6752 per share on the market, involving approximately HK$4.6752 million. After increasing his holdings, Qu Jiguang's latest shareholding was 1,117,706,000 shares, and the shareholding ratio increased from 37.61% to 37.65%.
石四藥集團:2023 年報
Zhitong Hong Kong Shareholders' Rights Disclosure | April 18
Disclosure of Hong Kong Stock Shareholders' Rights | April 18
Shi Siyao Group (02005.HK) obtained 800,000 shares from executive director Qu Jiguang
Gelonghui, April 18 | According to the latest equity disclosure data of the Stock Exchange, on April 17, 2024, Shijiyao Group (02005.HK) obtained executive director Qu Jiguang's holdings of 800,000 shares on the market at an average price of HK$4.763 per share, involving approximately HK$3.8104 million. After increasing his holdings, Qu Jiguang's latest shareholding was 1,116,706,000 shares, and the shareholding ratio increased from 37.58% to 37.61%.
Gelonghui Announcements Selected (Hong Kong Stocks) | Shijiyao Group (02005.HK) Net Profit Increased 14.6% to HK$416 Million in the First Quarter
[Today's Focus] Shijiyao Group (02005.HK): Net profit increased by 14.6% in the first quarter to HK$416 million. Shijiyao Group (02005.HK) announced that the group's sales were mainly carried out in China and were denominated in RMB. For the three months ending March 31, 2024, the RMB depreciated by about 3.6% against the Hong Kong dollar compared to the same period in 2023. As a result, in Hong Kong dollars, the Group's unaudited turnover for the three months ended 31 March 2024 increased by only 2.9% over the same period in 2023 to approximately HK$1,799 billion (same period in 2023: approximately HK$1,749 million).
SSY Group Logs Nearly 15% Boost in Q1 Profit
SSY Group (HKG:2005) recorded a 14.6% rise in attributable profit for the first quarter of 2024 to approximately HK$416 million, from HK$363 million a year earlier, a Monday filing on the Hong Kong bo
Shijiyao Group (02005.HK): Net profit increased 14.6% to HK$416 million in the first quarter
On April 16, Gelonghui | Shijiyao Group (02005.HK) announced that the Group's sales are mainly carried out in China and are denominated in RMB. For the three months ending March 31, 2024, the RMB depreciated by about 3.6% against the Hong Kong dollar compared to the same period in 2023. As a result, in Hong Kong dollars, the Group's unaudited turnover for the three months ended 31 March 2024 increased by only 2.9% over the same period in 2023 to approximately HK$1,799 billion (same period in 2023: approximately HK$1,749 million). Unaudited gross profit increased by 2.3% to approximately HK$1,031 million (same period 2023: approximately 1
SSY Group Provides Updates on Respiratory Infection, Hypertension Drugs
SSY Group (HKG:2005) said China's National Medical Products Administration (NMPA) approved the passing of Consistency Evaluation of the Quality and Efficacy of Generic Drugs for the Group's Cefalexin
Shisi Pharmaceutical Group (02005.HK): Cefadroxil capsules (0.25g and 0.125g) have obtained approval from the State Drug Administration to pass the consistent evaluation of generic drug quality and efficacy
Gelonghui, April 8, 丨 Shijiyao Group (02005.HK) announced that the Group's cephalexin capsules (0.25g and 0.125g) have obtained approval from the China National Drug Administration (“State Drug Administration”) to pass the consistent evaluation of the quality and efficacy of generic drugs. Cephalexin capsules are mainly used to treat acute tonsillitis, angina, sinusitis, bronchitis, pneumonia and other respiratory infections, otitis media, urinary tract infections, and skin and soft tissue infections caused by sensitive bacteria. Furthermore, the Board of Directors is also pleased to announce that the Group's doxazosin mesylate has been approved by the State Drug Administration and registered as a raw material for use in marketed formulations
Zhitong Hong Kong Shareholders' Rights Disclosure | April 8
Hong Kong Stock Shareholders' Rights Disclosure | April 8
Shishiyao Group (02005.HK) obtained 524,000 additional shares by Executive Director Qu Jiguang
Gelonghui, April 8, 丨 According to the latest equity disclosure data of the Stock Exchange, on April 5, 2024, Shijiyao Group (02005.HK) obtained executive director Qu Jiguang's holdings of 524,000 shares at an average price of HK$4.8152 per share on the market, involving approximately HK$2,523,200. After increasing his holdings, Qu Jiguang's latest shareholding was 1,115,906,000 shares, and the shareholding ratio increased from 37.57% to 37.58%.
Shi Siyao Group (02005.HK) obtained an increase of 1.5 million shares by Executive Director Qu Jiguang
Gelonghui, April 5 | According to the latest equity disclosure data of the Stock Exchange, on April 3, 2024, Shijiyao Group (02005.HK) obtained executive director Qu Jiguang's holdings of 1.5 million shares at an average price of HK$5,009 per share on the market, involving approximately HK$7,513,500. After increasing his holdings, Qu Jiguang's latest shareholding was 1,115,382,000 shares, and the shareholding ratio increased from 37.52% to 37.57%.
SSY Group's Two Drugs Get China's NMPA's Nod for Production and Registration
China's National Medical Products Administration (NMPA) granted approvals to SSY Group (HKG:2005) for drug production and registration for Cefuroxime Axetil for Suspension (0.25g and 0.125g) under typ
Shisi Pharmaceutical Group (02005.HK): It has obtained drug production registration approval from the State Drug Administration for cefuroxime dry suspensions (0.25g and 0.125g)
Gelonghui, April 3 | Shijiyao Group (02005.HK) announced that the Group has obtained drug production registration approval from the China National Drug Administration (“State Drug Administration”) for cefuroxime dry suspensions (0.25g and 0.125g), which is considered to have passed the consistency evaluation. Among them, the 0.25g specification was the first for a domestic company to be approved, and the 0.125g specification was the second to be approved. Cefuroxime dry suspension is mainly used to treat infectious diseases caused by sensitive bacteria. In addition, the Group has obtained lidocaine hydrochloride injections from the State Drug Administration (20m)
Zhitong Hong Kong Shareholders' Rights Disclosure | April 3
Disclosure of Hong Kong Stock Shareholders' Rights | April 3
Shi Siyao Group (02005.HK) obtained 2 million shares from executive director Qu Jiguang
Gelonghui, April 3 | According to the latest equity disclosure data of the Stock Exchange, on April 2, 2024, Shijiyao Group (02005.HK) obtained executive director Qu Jiguang's holdings of 2 million shares at an average price of HK$5.1221 per share on the market, involving approximately HK$10.244,200. After increasing his holdings, Qu Jiguang's latest shareholding was 1,113,882,000 shares, and the shareholding ratio increased from 37.45% to 37.52%.
Shishiyao Group (02005.HK) was increased by 500,000 shares by Executive Director Qu Jiguang
Gelonghui, April 2 | According to the latest equity disclosure data of the Stock Exchange, on March 28, 2024, Shijiyao Group (02005.HK) obtained executive director Qu Jiguang's holdings of 500,000 shares at an average price of HK$4.9037 per share on the market, involving approximately HK$2.452 million. After increasing his holdings, Qu Jiguang's latest shareholding was 1,111,882,000 shares, and the shareholding ratio increased from 37.43% to 37.45%.
No Data